Mylan (MYL) Unit Launches Generic Version of Sanofi-Aventis' (SNY) Plavix

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg. The company was the first to have filed a substantially complete ANDA containing a Paragraph IV certification to the FDA for Clopidogrel Tablets, 300 mg, and was awarded 180 days of marketing exclusivity for this strength.

This product is the generic version of Sanofi-Aventis' (NYSE: SNY) Plavix and is indicated for acute coronary syndrome and for patients with a recent history of myocardial infarction, stroke or established peripheral arterial disease.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Synaptics CFO resigns amid pending ON Semiconductor merger
• Professional Diversity Network forms AI subsidiary with no assets yet
• Virtus Investment Partners names Jack Boyce to its board